SGLT-2 inhibitors: a step forward in the treatment of heart failure with reduced ejection fraction

© Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. This is an open access article under the CC-BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Bibliographic Details
Main Author: Silva-Cardoso, José (author)
Other Authors: Andrade, Aurora (author), Brito, Dulce (author), Ferreira, Jorge (author), Fonseca, Cândida (author), Peres, Marisa (author), Franco, Fátima (author), Moura, Brenda (author)
Format: article
Language:eng
Published: 2021
Subjects:
Canagliflozin
Cardiovascular mortality
Dapagliflozin
Empagliflozin
Ertugliflozin
Heart failure
Heart failure hospitalization
SGLT-2 inhibitors
Sotagliflozin
Type-2 diabetes mellitus
Online Access:http://hdl.handle.net/10451/49549
Country:Portugal
Oai:oai:repositorio.ul.pt:10451/49549

Internet

http://hdl.handle.net/10451/49549

Similar Items